Venetoclax-Based Regimen Shows Promising Survival in Ph- ALL
A phase 2 study found that a venetoclax-based regimen significantly improved survival rates in adolescents and adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia compared to historical chemotherapy cohorts. The study reported high rates of measurable residual disease negativity and overall survival, although it noted an increased incidence of certain adverse events. Researchers emphasized the regimen's potential benefits while acknowledging its associated treatment-related toxicity.
- ▪The venetoclax-based regimen achieved a 78.5% estimated 2-year overall survival rate.
- ▪Among 160 patients assessed, 91% achieved complete remission after induction chemotherapy.
- ▪The regimen was associated with a higher rate of grade ≥ 3 intestinal obstruction compared to historical cohorts.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:A venetoclax-based pediatric-inspired regimen achieved high rates of postinduction measurable residual disease negativity and was associated with improved survival compared with a propensity score-matched historical chemotherapy cohort among adolescents and adults with newly diagnosed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL), according to a phase 2 study. The overall incidence of grade ≥ 3 adverse events was similar to that observed in the historical cohort, but the venetoclax-based regimen was associated with a markedly higher rate of grade ≥ 3 intestinal obstruction (18.1% vs 5.6%) as well as treatment-related deaths during induction.METHODOLOGY:Adolescents and adults with Ph- ALL generally have worse survival outcomes than children.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
